SEC Form 4 · accession 0001104659-17-041012
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Lettmann
Director · 10% Owner
Period of report
Jun 20, 2017
Accepted (ET)
Jun 22, 2017 · 7:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2,F1 | $22.37 | Jun 20, 2017 | A | 15,000 | A | — | Jun 20, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.
- F2The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.